Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,062 recruiting studies in this area right now.
By phase
- Not applicable3,004
- Phase 21,058
- Phase 1794
- Phase 1/Phase 2439
- Phase 3436
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis329
- Multiple Myeloma328
- Asthma193
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus119
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases77
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca63
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California497
- Maryland199
- Alabama177
- Florida152
- Arizona148
- Massachusetts117
- New York116
- Texas112
- Colorado82
- Illinois82
Recruiting studies6,062 total
- NCT07296276Recruiting
Testing the CareSens Air 3 glucose monitor in type 1 diabetes
This study tests how accurate a new continuous glucose monitor (CGM) called CareSens Air 3 is for adults with type 1 diabetes. You would wear the sensor on your skin to track blood sugar levels, and it may help you manage your diabetes more easily.
Escondido, CaliforniaAges 18–65 - NCT07290803Recruiting
Atopic dermatitis treatment registry for teens and adults
This study is a long-term registry for adolescents and adults with atopic dermatitis (eczema) who are starting or switching to a systemic medication (a drug that works throughout the body). It will track how these treatments work in real life and how patients feel over time.
Birmingham, AlabamaAges 12 years+ - NCT07294365RecruitingPhase 2
Study of DZD8586 for adults with chronic ITP
This study tests an investigational drug called DZD8586 for people with long-term ITP (low platelets) that hasn't improved with standard treatments. The goal is to see if it can safely raise platelet counts and reduce bleeding risk.
Jinan, ShandongAges 18 years+ - NCT07290777RecruitingPhase 2
Study of Vel-101 to prevent kidney transplant rejection
This trial tests a new medicine called VEL-101, which is added to standard anti-rejection drugs, to see if it helps prevent the body from rejecting a new kidney. It is for adults receiving a kidney from a deceased or non-identical living donor.
Dallas, TexasAges 18 years+ - NCT07288515Recruiting
Acalabrutinib for CLL in routine care
This study follows people with CLL who are starting acalabrutinib (a targeted pill) for the first time, either as their first treatment or after previous therapies. The goal is to see how well it works in everyday medical practice.
GrodnoAges 18 years+ - NCT07291323RecruitingEarly Phase 1
Safety study of JANX011 in healthy adults
This trial tests a new drug called JANX011 in healthy adults to see if it is safe and well tolerated. It is a first step before testing in patients.
Adelaide, South AustraliaAges 18–65 - NCT07293871Recruiting
Ultrasound treatment for rheumatoid arthritis
This trial tests whether ultrasound waves applied to the spleen can reduce inflammation in adults with rheumatoid arthritis. It is for people with moderate to severe disease who have not tried many biologic medications.
Colleyville, TexasAges 18 years+ - NCT07289763RecruitingPhase 2
Study of SHR-2173 for primary membranous nephropathy
This trial tests an investigational drug called SHR-2173 for people with primary membranous nephropathy, a kidney disease that causes protein leakage. The study aims to see if the drug is safe and effective, and it involves periodic injections and monitoring.
Nanjing, JiangsuAges 18–75 - NCT07295847RecruitingPhase 1
Study of AZD0120 for autoimmune diseases
This trial tests if a new medication, AZD0120, is safe for people with autoimmune diseases. It aims to help patients by targeting the immune system.
Tucson, ArizonaAges 18–75 - NCT06664918Recruiting
Milk ladder therapy for children with cow's milk allergy
This study tests whether a gradual 'milk ladder' approach (slowly introducing milk in increasing amounts) is safe and effective for children with cow's milk allergy. It may help your child eventually tolerate milk.
WarsawAges 1–5 - NCT06453512Recruiting
Testing Doublebase Once Moisturizer for Atopic Eczema
This study tests a moisturizer called Doublebase Once for people with atopic eczema. You apply it once a day for 4 weeks to see how well it improves skin moisture and eczema symptoms.
Nottingham, NottinghamshireAges Any age - NCT06224634Recruiting
Testing a new drug for airway problems
This trial tests how a drug called anti-IL-17 affects your airways. If you are already planning to take this drug, researchers want to see if it helps with breathing and airway resistance.
Hvidovre, Capital RegionAges 18 years+ - NCT06758037RecruitingPhase 2
HiR Plus X therapy for elderly DLBCL patients who can't have chemo
This study tests a new treatment called HiR+X for older adults with a type of lymphoma (DLBCL) who cannot tolerate standard chemotherapy. It aims to offer a gentler but effective option.
Ningbo, ZhejiangAges 70–100 - NCT06882148Recruiting
How long do eczema patients stay on targeted therapies?
This study looks at how long people with moderate to severe eczema stay on newer targeted medicines (biologics or pills). By reviewing medical records, researchers hope to learn which treatments work best over time and how they are used in real life.
RomeAges 18 years+ - NCT07279467Recruiting
Peanut allergy food challenge biomarker study
This study aims to identify markers in the blood that could help predict how severe a peanut allergy reaction might be. If you qualify, your child will undergo a supervised peanut challenge to see how their body responds.
Little Rock, ArkansasAges 1–17 - NCT07281456RecruitingPhase 2
Testing a new oral drug for Sjögren's disease safety
This study tests the safety of a daily pill called Tofacitinib for adults with mild-to-moderate Sjögren's disease. It aims to see if this drug helps manage symptoms when other treatments haven't worked well.
Bethesda, MarylandAges 18–75 - NCT07282574RecruitingPhase 2
Study of an add-on drug for progressive multiple sclerosis
This trial tests whether adding a new medication, RO7268489, to the standard treatment ocrelizumab (Ocrevus) can help people with progressive forms of multiple sclerosis (MS) by slowing disability progression. The trial will evaluate the safety and effectiveness of this combination approach.
Camperdown, New South WalesAges 18–60 - NCT07284797RecruitingPhase 1
Safety study for autoimmune disease and healthy volunteers
This trial is testing an experimental drug for safety in people with certain autoimmune diseases—like myositis, scleroderma, or Sjögren's disease—as well as in healthy volunteers. It aims to find out if the drug is safe enough to study further.
MelbourneAges 18–75 - NCT07280013RecruitingPhase 1
Cemsidomide with elranatamab for multiple myeloma
This trial tests a new drug combination (cemsidomide and elranatamab) for people with multiple myeloma that has come back after previous treatments. The goal is to see if the combination is safe and works better than current options.
Gilbert, ArizonaAges 18 years+ - NCT07287033RecruitingPhase 1
Safety study of MY006 in healthy people and people with peanut allergy
This early-phase study tests a new investigational medication (MY006) to see if it is safe and how the body processes it. It is given to both healthy volunteers and people with peanut allergy. The goal is to gather safety information before larger trials.
Little Rock, ArkansasAges 12–55 - NCT07286656RecruitingPhase 1
A study of GensSci098 for Graves' disease
This study tests a new investigational drug called GensSci098 for people with Graves' disease who have not taken antithyroid medication recently. It aims to see if the drug can help manage thyroid hormone levels.
Shenyang, LiaoningAges 18 years+ - NCT07284927RecruitingPhase 1
LV009 injection for blood and lymph cancers
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
Suzhou, JiangsuAges 18–70 - NCT07286006Enrolling by invitationPhase 2
Long-term safety study of IMVT-1402 for Graves' disease
This study is a long-term extension for people with Graves' disease who already completed a previous study with the drug IMVT-1402. It aims to see how safe and effective the drug is over a longer period.
Phoenix, ArizonaAges 18 years+ - NCT07284758RecruitingPhase 2
Cemsidomide and dexamethasone for relapsed/refractory multiple myeloma
This clinical trial tests a new combination of two medicines (cemsidomide and dexamethasone) for people with multiple myeloma that has come back or stopped responding after at least three prior treatments. The goal is to see if this new drug can help control the cancer when other options have stopped working.
Huntsville, AlabamaAges 18 years+
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,062 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,151 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.